• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

Load-dependent surface diffusion model for analyzing the kinetics of protein adsorption onto mesoporous materials

2 de October de 2017
J Colloid Interface Sci. 2018 Feb 1;511:27-38. doi: 10.1016/j.jcis.2017.09.091.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-10-02 10:00:002017-10-02 10:00:00Load-dependent surface diffusion model for analyzing the kinetics of protein adsorption onto mesoporous materials

Fatty acid synthase (FASN) as a therapeutic target in breast cancer

19 de September de 2017
Expert Opin Ther Targets. 2017 Nov;21(11):1001-1016. doi: 10.1080/14728222.2017.1381087.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-09-19 10:00:002017-09-19 10:00:00Fatty acid synthase (FASN) as a therapeutic target in breast cancer

Targeting STAT3 with silibinin to improve cancer therapeutics

8 de July de 2017
Cancer Treat Rev. 2017 Jul;58:61-69. doi: 10.1016/j.ctrv.2017.06.003.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-07-08 10:00:002017-07-08 10:00:00Targeting STAT3 with silibinin to improve cancer therapeutics

EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells

1 de June de 2017
Oncol Rep. 2017 Jul;38(1):263-270. doi: 10.3892/or.2017.5682.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-06-01 10:00:002017-06-01 10:00:00EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells

Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer

23 de May de 2017
Front Cell Dev Biol. 2017 May 5;5:49. doi: 10.3389/fcell.2017.00049.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-05-23 10:00:002017-05-23 10:00:00Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer

Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab

8 de April de 2017
Cell Cycle. 2017 Jun 3;16(11):1022-1028. doi: 10.1080/15384101.2017.1310353.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-04-08 10:00:002017-04-08 10:00:00Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells

8 de April de 2017
Oncotarget. 2017 May 23;8(21):35019-35032. doi: 10.18632/oncotarget.16558.ABSTRACTDenosumab,…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-04-08 10:00:002017-04-08 10:00:00BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells

Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells

28 de February de 2017
Oncogenesis. 2017 Feb 27;6(2):e299. doi: 10.1038/oncsis.2017.4.ABSTRACTFatty…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-02-28 11:00:002017-02-28 11:00:00Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells

Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users

18 de February de 2017
Nutrients. 2017 Feb 10;9(2):121. doi: 10.3390/nu9020121.ABSTRACTMetabolic…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-02-18 11:00:002017-02-18 11:00:00Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users

Nuclear reprogramming of cancer stem cells: Corrupting the epigenetic code of cell identity with oncometabolites

17 de January de 2017
Mol Cell Oncol. 2016 Mar 28;3(6):e1160854. doi: 10.1080/23723556.2016.1160854.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-01-17 11:00:002017-01-17 11:00:00Nuclear reprogramming of cancer stem cells: Corrupting the epigenetic code of cell identity with oncometabolites

Metformin targets histone acetylation in cancer-prone epithelial cells

30 de October de 2016
Cell Cycle. 2016 Dec 16;15(24):3355-3361. doi: 10.1080/15384101.2016.1249547.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-10-30 10:00:002016-10-30 10:00:00Metformin targets histone acetylation in cancer-prone epithelial cells

STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer

19 de October de 2016
Cell Cycle. 2016 Dec 16;15(24):3413-3418. doi: 10.1080/15384101.2016.1245249.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-10-19 10:00:002016-10-19 10:00:00STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer
Page 10 of 11«‹891011›

Filter by categories

  • Alemany’s & Piulats’s lab (131)
  • Antolin's lab (36)
  • Aytes's Lab (24)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sureda's & Farre's Lab (259)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}